AI System Co-Scientist Spots Mechanism Behind MASH Drug's Limits
Edinburgh bioengineer Filippo Menolascina used Co-Scientist to explain why resmetirom helps few MASH patients, pinpointing the NLRP3 inflammasome — a hypothesis later verified in the lab.